Silo Pharma Inc
silopharma.comWhat Do They Do?
Develops drug candidates for psychiatric, chronic-pain and central nervous system conditions, and holds digital assets in blockchain networks to earn rewards.
10-K for FY2025, filed Mar 27, 2026We are a developmental stage biopharmaceutical and cryptocurrency company. Our therapeutics focus is on developing novel therapeutics that…View ↗
We seek to acquire and/or develop intellectual property or technology rights from leading universities and researchers to treat rare…View ↗
Our strategy changed to include cryptocurrency treasury strategy in August 2025 to focus on the acquisition of leading digital assets.…View ↗
The Company has staked $98,584 of crypto assets, at cost as of December 31, 2025. The Company’s ability to sell or transfer staked digital…View ↗
How Do They Make Money?
The company earns license and royalty income from license agreements. Payments from licensees for future periods are spread over the agreement term.
10-K for FY2025, filed Mar 27, 2026For the license and royalty income, revenue is recognized when the Company satisfies the performance obligation based on the related…View ↗
$72.1K
-
10-K for FY2025, filed Mar 27, 2026
$72.1K ↗
Who Are Their Customers?
A licensee obtains rights under a license agreement and pays the company license fees.
10-K for FY2025, filed Mar 27, 2026
10-K for FY2025, filed Mar 27, 2026
For the years ended December 31, 2025 and 2024, one licensee accounted for 100% total revenues from customer license fees.View ↗
Do Revenues Turn Into Profits?
No. It lost $4.2M in FY2025.
10-K for FY2025, filed Mar 27, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 13, 2026
−$832.8KView ↗
- ▼ −31% (Loss)
- vs −$1.2M in Q2 FY2025
-
Aug 19, 2026
Bought software, technology and related intellectual-property assets
Sources
8-K, filed Aug 19, 2026
On August 18, 2026, Silo Pharma, Inc. (the “Company”) entered into an asset purchase agreement (the “Agreement”) with Parkview Consulting…View ↗
-
Apr 2, 2026
Bought QwikAgents web application software and related domains
The company issued common shares to the seller for the assets.
Sources
8-K, filed Apr 2, 2026
On July 29, 2025, Silo Pharma, Inc. (the “Company”) entered into an asset purchase agreement (the “Agreement”) with Many Ads Inc. (the…View ↗
Growing. Revenue grew 59.6x in 4 years, from $1.2K in FY2021 to $72.1K in FY2025, about 178% a year.
Digital-asset treasury strategy
The older report focuses on developing therapeutics and licensing research rights; the latest adds holding and staking digital assets as a treasury strategy alongside drug development.
10-K for FY2022, filed Mar 24, 2023 10-K for FY2025, filed Mar 27, 2026Our strategy changed to include cryptocurrency treasury strategy in August 2025 to focus on the acquisition of leading digital assets.…View ↗
Loading...
